| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 01/09/2002 | CN1330662A Heliobacter pylori antigen |
| 01/09/2002 | CN1330658A Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| 01/09/2002 | CN1330640A Cyclic hydrazine derivatives as TNF-alpha inhibitors |
| 01/09/2002 | CN1330631A Amide derivatives which are useful as cell factor inhibitors |
| 01/09/2002 | CN1330557A In situ injection of antigen-presenting cells with generatically enhanced cytokine expression cell factor |
| 01/09/2002 | CN1330553A Adjuvant systems and vaccines |
| 01/09/2002 | CN1330552A Oral vaccine against diarrhea |
| 01/09/2002 | CN1330547A Pharmaceutical formulations |
| 01/09/2002 | CN1330546A Compositions comprising cefuroxime axetil |
| 01/09/2002 | CN1330532A Oil-in-water emulsion comprising micronised biologically active agent and appropriate emulsified system |
| 01/09/2002 | CN1330081A Single-chain antibody resisting HIV-1 outer membrane protein and recombinant immunotoxin |
| 01/09/2002 | CN1330073A Peptide nucleic acid derivatives, intermediate for preparing them and medicinal composition containing them |
| 01/09/2002 | CN1329889A Concentrated granular medicine for treating baby cold and preparation process thereof |
| 01/09/2002 | CN1077439C Labeled chemotactic peptides to image focal sites of infection or inflammation |
| 01/08/2002 | US6337411 Muscular disorders |
| 01/08/2002 | US6337403 Triazole derivatives having antifungal activity |
| 01/08/2002 | US6337350 Inhibitors of formation of advanced glycation endproducts (AGEs) |
| 01/08/2002 | US6337339 Methods and compositions for treating infection using optically pure (S)-lomefloxacin |
| 01/08/2002 | US6337329 Vision defects and antiinflammatory agents |
| 01/08/2002 | US6337324 Pharmaceutical combination |
| 01/08/2002 | US6337317 Amino acid sequence peptides as microbiocides |
| 01/08/2002 | US6337090 Orally administrable solid ribavirin dosage forms and process for making them |
| 01/08/2002 | US6337073 Administering intranasally a live, attenuated yellow fever virus to a human for inducing a binding and a neutralizing antibody response to provide immunity |
| 01/08/2002 | US6337070 Polypeptides for use in generating anti-human influenza virus antibodies |
| 01/08/2002 | CA2344471C Hydrogen peroxide disinfectant with increased activity |
| 01/08/2002 | CA2165821C Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection |
| 01/03/2002 | WO2002102789A1 Antimicrobial and radioprotective compounds |
| 01/03/2002 | WO2002000919A2 Screen for identifying inhibitors of glycosylphosphatidylnositol anchoring |
| 01/03/2002 | WO2002000894A2 Gene silencing vector |
| 01/03/2002 | WO2002000885A2 Assembly of wild-type and chimeric influenza virus-like particles (vlps) |
| 01/03/2002 | WO2002000883A2 Rescue of canine distemper virus from cdna |
| 01/03/2002 | WO2002000882A2 Transport peptides dirived from erns protein, cytotoxic rnase of ribosome-inactivating protein or a rsv g-protein and analogues thereof |
| 01/03/2002 | WO2002000881A1 Bvdv virus-like particles |
| 01/03/2002 | WO2002000860A2 Novel proteases |
| 01/03/2002 | WO2002000839A2 Statement as to federally sponsored research |
| 01/03/2002 | WO2002000836A2 Spinigerin variants, an antibacterial and antifungal peptide derived from pseudacanthotermes spiniger, preparation method and compositions containing same |
| 01/03/2002 | WO2002000730A2 Pd-l2 molecules: novel pd-1 ligands and uses therefor |
| 01/03/2002 | WO2002000728A2 Methods and compositions for isolating biologically active antibodies |
| 01/03/2002 | WO2002000727A2 Gp286 nucleic acids and polypeptides |
| 01/03/2002 | WO2002000695A2 Peptides for the preparation of vaccines against bordetella pertussis and bordetella parapertussis |
| 01/03/2002 | WO2002000693A2 Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes |
| 01/03/2002 | WO2002000692A2 Pd-l2 molecules: pd-1 ligands and uses therefor |
| 01/03/2002 | WO2002000691A2 Polynucleotides and polypeptides encoded thereby |
| 01/03/2002 | WO2002000687A2 Antimicrobial peptides and methods of use thereof |
| 01/03/2002 | WO2002000676A1 Purine derivatives |
| 01/03/2002 | WO2002000663A2 Polycyclic xanthones as antibiotics |
| 01/03/2002 | WO2002000662A1 Improvements in and relating to chromophores |
| 01/03/2002 | WO2002000650A2 Novel compounds possessing antibacterial, antifungal or antitumor activity |
| 01/03/2002 | WO2002000639A1 Synthesis of cyclic compounds |
| 01/03/2002 | WO2002000632A1 Benzodiazepines as inhibitors of hpv e1 helicase |
| 01/03/2002 | WO2002000616A2 Novel cephalosporin compounds and process for preparing the same |
| 01/03/2002 | WO2002000613A2 Inhibitors of hepatitis b virus infection |
| 01/03/2002 | WO2002000593A2 Compounds useful for the preparation of medicaments with phosphodiesterase iv inhibitory activity |
| 01/03/2002 | WO2002000266A2 A method of treating and preventing infectious diseases |
| 01/03/2002 | WO2002000263A2 Tripeptide prodrug compounds |
| 01/03/2002 | WO2002000252A2 Non-human animal models of tolerance to hepatitis c virus immunogenes |
| 01/03/2002 | WO2002000251A1 Vaccine against foot-and-mouth disease |
| 01/03/2002 | WO2002000250A2 Hiv-1 vaccines and screening methods therefor |
| 01/03/2002 | WO2002000249A2 Multivalent vaccine composition |
| 01/03/2002 | WO2002000247A1 Reversal of antibiotic resistance with lysozyme dimer |
| 01/03/2002 | WO2002000242A2 Human papilloma virus treatment |
| 01/03/2002 | WO2002000220A1 A method for treating septic shock |
| 01/03/2002 | WO2002000219A1 Sustained-release preparations of quinolone antibiotics and method for preparation thereof |
| 01/03/2002 | WO2002000217A1 Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators |
| 01/03/2002 | WO2002000203A1 Topical pharmaceutical formulations and methods of treatment |
| 01/03/2002 | WO2002000201A2 Method for preparing a composition |
| 01/03/2002 | WO2002000168A2 Combination hiv therapy including camptothecin |
| 01/03/2002 | WO2002000167A2 Modified forms of pharmacologically active agents and uses therefor |
| 01/03/2002 | WO2002000166A2 New compounds useful as antibacterial agents |
| 01/03/2002 | WO2002000165A2 Agent for reversal of drug resistance in mycobacterium tuberculosis |
| 01/03/2002 | WO2002000163A2 The method of treating drug resistant mycobacterium tuberculosis infection |
| 01/03/2002 | WO2002000161A1 Medicinal product package for eradication therapy |
| 01/03/2002 | WO2001071005A3 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 01/03/2002 | WO2001070693A3 Difluorobutyric acid derivatives and their use as metalloprotease inhibitors |
| 01/03/2002 | WO2001051473A8 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation |
| 01/03/2002 | WO2001049713A3 Stabilizing peptides, polypeptides and antibodies which include them |
| 01/03/2002 | WO2001046696A3 Methods and compositions for detecting hepatitis e virus |
| 01/03/2002 | WO2001046383A3 Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein |
| 01/03/2002 | WO2001045726A3 The use of procyanidins in the modulation of cytokine gene expression and protein secretion |
| 01/03/2002 | WO2001041800A3 Compositions and methods for stabilizing biological molecules upon lyophilization |
| 01/03/2002 | WO2001032877A3 CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO |
| 01/03/2002 | WO2000061171A9 Uses of mammalian ox2 protein and related reagents |
| 01/03/2002 | US20020002279 Heat resistance; storage stability |
| 01/03/2002 | US20020002272 Eliciting HCV-specific antibodies |
| 01/03/2002 | US20020002269 Artemin, a neurotrophic factor |
| 01/03/2002 | US20020002203 Administering an effective amount of a compound selected from aryl(and heterocyclic) ureido and aryl(heterocyclic) carboxamido phenoxyisobutyric acids as inhibitor of glycation and advanced glycation endproducts (AGEs) (protein-aging) |
| 01/03/2002 | US20020002180 A synergistic mixture of lamivudine and BMS-200475 for the treatment of a Hepititis B viral infection; effective against mutants resistant to nucleoside and/or non-nucleoside inhibitors of the replication of the HBV |
| 01/03/2002 | US20020002178 Antiproliferative, -carcinogenic agents, antiinflammatory and -arthritis agents; neurodegenerative diseases, e.g., Alzheimer's disease; cardiovascular disorders; viricides; fungicides |
| 01/03/2002 | US20020002166 Use of MKC-442 in combination with other antiviral agents |
| 01/03/2002 | US20020002160 Process for formulation of antibiotic compounds |
| 01/03/2002 | US20020002151 Minocycline-containing compositions |
| 01/03/2002 | US20020002147 Stabilizing amount of magnesium stearate; extended dosage formed by extrusion and spheronization and coated with a seal coating; nucleoside reverse transcriptase inhibitor; treatment of retroviruses, HIV |
| 01/03/2002 | US20020002145 Adenosine A2A receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver |
| 01/03/2002 | US20020002143 AIDS virus vaccines using sendai virus vector |
| 01/03/2002 | US20020002133 Stabilized granulocyte colony stimulating factor |
| 01/03/2002 | US20020001798 Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
| 01/03/2002 | US20020001616 Novel method of treatment |
| 01/03/2002 | US20020001600 Method of using lectins for prevention and treatment of skin diseases and disorders |
| 01/03/2002 | US20020001597 Eliciting in vertebrate a protective immune response against bacterium of the genus Chlamydia; carrier group coupled to oligosaccharide |
| 01/03/2002 | US20020001595 Sampling antigen-containing blood and/or tissue; obtaining liquid/homogenate; adding crosslinking agent; heating to solidification; mixing with pyrogen-free salt solution; for treatment of AIDS, HIV |